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Neurofibrillary tangles, composed of intracellular aggregates of
tau protein, are a key neuropathological feature of Alzheimer’s
disease and other neurodegenerative diseases, collectively termed
tauopathies. Tau research has become one of the central players
in the investigation of neurodegenerative diseases. Tau protein
has several unique characteristics such as natively unfolded con-
formation, thermo-stability, acid-stability, and capability of post-
translational modifications. We still do not know whether tau itself
is toxic. With certain triggers, tau may transit into toxic forms.
Researchers are now looking for “tau oligomers” as toxic com-
ponents. Because “tau oligomers” contain variable species of tau
protein [e.g., dimer (disulfide bond-dependent or -independent),
multimer (more than dimer), granular (defined as EM or
AFM) and perhaps small filamentous aggregates] (Figure 1),
it is important to have a consensus regarding the definition,
FIGURE 1 | Schematic illustration of the central role of tau oligomers in tauopathies. Figure taken from Gerson and Kayed (1).
terminology, and methodology for the identification of “tau
oligomers” (1–6).
Recently, “prion-like” toxicity and propagation mechanisms
underlying the progression of disease have been proposed. With
this concept, tau may have the ability to translocate between neu-
rons and amplify toxic components (7). Although we do not know
the exact forms of toxic tau oligomers, accumulating evidence has
shown the probability of tau oligomer propagation (6).
Tau is an intracellular microtubule-associated protein. The
mechanism of tau transmission from cell to cell is still unknown.
Research focusing on extracellular tau will open potential new
avenues for discovering the mechanism of tau propagation (8).
Abnormally hyperphosphorylated tau is a key feature of human
tauopathies. Although we are not sure whether phosphorylation
rather than oligomerization of tau is an initial molecular event in
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tau pathogenesis, investigating the regulatory mechanisms of tau
phosphorylation will be essential (9–11).
Here, we provide an overview of the current understandings of
“tau oligomers” (1–12). Efforts toward the identification of neuro-
toxic tau species will ultimately lead to the translational research
for developing novel therapeutic strategies for tauopathies.
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